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Interferonswereﬁrstdescribedin1957,butitwasnotuntil34yearsaftertheirdiscoverythatsuﬃcientquantitiesofitwereavailable
fortreatmentofhepatitisCvirus(HCV)infections,Cliniciansnowhaveanexcellentunderstandingofthebasisfortheeﬀectiveness
of interferon alpha (IFN-α) in the therapy of this disease. Treatment with IFN-α is more eﬃcient when it complemented by the
antiviral ribavirin and the IFN-α is conjugated with polyethylene glycol to form peginterferon. In the near future treatment of
HCV with IFN-α may involve new anti-HCV agents that are currently under development.
The antiviral activity of interferon (IFN), ﬁrst described in
1957, was in a chick cell and inactivated inﬂuenza virus
system [1]. The inactivated virus induced a protein that had
a broad spectrum of antiviral activity, which immediately
attracted wide interest, so that there was expectation that
interferons (IFNs) rapidly would develop clinically as agents
to treat a range of viral infections. In addition to their
antiviral activity, IFNs were later discovered to be important
regulators of both cellular growth and the immune response.
A number of problems arose, however, that delayed their
clinical use for the treatment of virus infections for many
years. The ﬁrst of these was that the IFNs, with some
exceptions, are species-speciﬁc in their biological activity
[2], so that only human or primate interferons were found
to be active in humans. This meant that the single source
of interferons for human use in the 1960s and 70s was
primate cells, and the supply of such cells was quite limited.
Another problem was that IFNs could only be assayed by
means of their ability to inhibit virus replication in a tissue
culture system [1]. In addition, IFNs were found to possess
thenunprecedentedbiologicalactivity,anditbecameevident
that existing stocks of IFNs with very signiﬁcant antiviral
activity actually were quite impure and so contained very
little IFN. Because of the lack of even moderately clean IFN,
it was impossible to accept any biological activity of an IFN
preparation, other than antiviral activity, as being due to
its IFN content, although subsequently IFNs were shown to
have many biological functions. Despite such problems, and
because of the promise IFNs held as a possible treatment for
viral diseases, there were early clinical trials of the antiviral
activity of what IFN preparations were then available. These
studies tested the ability of an IFN produced by simian
cells to inhibit the development of vaccinia virus lesions
in human skin or respiratory infections following exposure
of volunteers to common cold viruses [3, 4]. The results
were unimpressive, almost certainly because of the small
quantities of impure IFN used, so that for many years studies
on IFNs were limited to experiments in tissue culture and to
attempts to produce and purify suﬃcient quantities of IFN
from human cells to carry out signiﬁcant clinical studies. To
further complicate matters, it was discovered that there were
actually several forms of human IFN, IFNs-α,- β,a n d- γ.
T h e r ea r es e v e ns u b t y p e so fh u m a nI F N - α, but only single
genes coding for IFNs-β and -γ. Subsequently, additional
forms were discovered, but only IFNs -α,- β,a n d- γ are
presently used clinically.
Interest in IFNs was reignited in the mid-1970s when
suﬃcient quantities of fairly clean human IFN-α, obtained
by Cantell’s group in Finland from the white blood cell buﬀy
coats of donated blood, became available [5] for clinical2 Hepatitis Research and Treatment
experiments. Many of these had promising, if not highly
signiﬁcant, results in studies on the prevention of common
colds [6]andthetreatmentofseveralherpesvirusinfections,
such as herpes keratoconjunctivitis and the varicella-zoster
infections,shinglesandchickenpox [7,8].Thediscoverythat
in tissue culture experiments mouse IFN-β inhibited chronic
infections with mouse leukemia viruses [9] prompted addi-
tional studies employing interferon as therapy for human
chronic hepatitis B virus (HBV) infections. These had very
promising results [10].
A 1974 report that Cantell’s IFN-α was an eﬀective
treatment for cancer, although later shown to be ﬂawed,
nevertheless had profound eﬀects on interferon research,
bothpositiveandnegative[11].ThatIFNsmightbepotential
anticancer drugs led to widespread, unwarranted, and later
disappointed expectations of their being a general cure for
cancer; on the positive side, however, interest in ﬁnding
better sources for a potential wonder drug led directly to
the cloning of genes for human IFN-α [12], and later for
IFNs-β and -γ [13, 14]. This in turn led to the production
of quantities of pure IFNs suﬃc i e n tt oc a r r yo u tal a r g e
number of clinical trials with signiﬁcant results. Such studies
have partially clariﬁed what the role of IFNs might be in the
treatment of several diseases. Recombinant IFN-αsp r e s e n t l y
are widely employed with some success in the treatment
of chronic hepatitis B virus (HBV) and hepatitis C virus
(HCV) infections and with limited eﬀectiveness, in some
formsof neoplasia suchasmelanomas[15].IFN-β treatment
is regularly used to limit exacerbations of multiple sclerosis
[16]. IFN-γ has been approved for clinical use only in
a rare congenital disorder, chronic granulomatous disease,
for which it is eﬀective in preventing recurrent bacterial
infections. Current clinical trials are underway employing in
the treatment of chronic HBV and HCV infections IFN-λ,
which is biologically similar to IFNs-α and -β,b u te m p l o y sa
diﬀerent membrane receptor [17, 18]. Phase 1 trials for IFN-
λ were successfully completed in October, 2009, and Phase 2
trials have been initiated.
By far the best understood clinical application of IFNs
biologically is against chronic HCV infections, for which
IFN-α has been an approved treatment since 1991, although
IFN treatment for HCV was ﬁrst employed in 1986 with
some promise, well before the viral cause of the infection
had been identiﬁed [19, 20]. HCV is a widespread infec-
tion spread by contaminated blood products or by drug
injection. Although modern blood bank technology has
almost eliminated the former, the latter remains a major
problem. There are worldwide millions of HCV-infected
patients. The progress of HCV infections is insidious, often
not being clinically manifest for two or three decades after
initial infection with the virus. Chronic HCV infection
may cause serious hepatic malfunction eventually resulting
in cirrhosis of the liver and in life-threatening esophageal
varices. In addition, a signiﬁcant number of patients with
chronic HCV infections eventually develop hepatocellular
cancers (hepatomas) and have an increased risk for devel-
oping renal cell carcinomas [21]. Chronic infections with
HCV are a signiﬁcant cause of death in patients with
AIDS [22].
HCV is a small Flavivirus, the sole member of the
hepacivirusribovirusspecies,withsevengenotypes,ofwhich
genotype 1, unfortunately the most common infection in
N o r t hA m e r i c a ,i sr e l a t i v e l yi n s e n s i t i v et oI F N - α.I ta p p e a r s
possible to predict the response of a patient to infection
with a genotype 1HCV isolate by use of structural analysis
of the infecting virus [23]. The core protein of genotype
1HCV induces cellular proliferation and transformation
and so is associated with advanced hepatic cirrhosis and
hepatocellulartransformation[24].TheresistanceofHCVto
IFN resides in a nonstructural viral protein NS3/4A, a serine
protease that inactivates the signal leading to interferon
production, thus apparently facilitating the development
of chronic infections [25]. IFNs-α and -β production is
induced when a cellular protein receptor, RIG-1 (retinoic
acid inducible gene), is activated by single-strand virus
RNA. Activated RIG-1 in turn interacts with the adaptor
mitochondrial antiviral signaling (MAVS) protein that phos-
phorylates IFN response factor 3 (IRF3), leading eventually
to production of IFN [26]. The viral NS3/4 protease inhibits
interferon production by hydrolyzing the attachment of
MAVS to its site on mitochondria. HCV growth is, how-
ever, sensitive to the antiviral action of IFN although the
mechanism for this inhibition is presently uncertain. It may
involve two of the proteins induced by IFN treatment, a
ribonuclease thatdestroysHCVRNAoraproteinkinase that
inactivates a factor required for virus protein synthesis [27].
The expression of the gene for IL-28B, which codes for IFN-
λ, is a predictor of the ability of patients to clear HCV or to
respond to therapy for HCV infections [28]. Patients with
severe cases of HCV appear to respond to IFN therapy better
than do patients with more moderate infections [29].
In order to augment the eﬀectiveness of IFN-α employed
in the treatment of HCV, two alterations in the protocol
for its treatment were initiated. Ribavirin, an oral purine
analogue that inhibits the growth of some RNA viruses, such
as ﬂaviviruses, either by inhibiting the HCV polymerase or
by inducing lethal virus mutations among other possible
mechanisms, was added to the regimen [30]; and IFN-α
was conjugated to polyethylene glycol to yield peginterferon.
This conjugation decreases the renal clearance of the IFN
and so signiﬁcantly increases its half-life from about 5h
to almost 90h, which in turn allows a reduction in the
required frequency of treatments [31, 32]. Of the two forms
of peginterferon available, peginterferon alfa-2a appears to
be somewhat more eﬀective than does peginterferon alfa-
2b [33, 34]. With the combined ribavirin/peginterferon
treatment, more than 75% of nongenotype 1 HCV patients
maintain a sustained anti-HCV response, and up to 50% of
the patients infected with the genotype 1HCV responded
to this combined treatment; in those patients responding to
peginterferon/ribavirin therapy, virus-induced liver damage
failed to progress, with some degree of healing taking place
[31]. IFN-based treatment was associated with improved
survival and reduced the risk of hepatocellular cancer.
Long-term followup indicated that once a particular HCV-
infected patient attains a sustained response to peginter-
feron/ribavirin therapy, deﬁned as undetectable levels of
HCV RNA in the serum for six months, the risk for virologicHepatitis Research and Treatment 3
relapse is very low [35]. In one clinical study, low doses of
peginterferon and ribavirin were as eﬀective as higher dose
levels [24, 36].
Current treatments for chronic HCV infections have
several limitations, as they result in rates of sustained virus
responsesthatwerelowerinblackandLatinopatientsthanin
non-Latinowhites[37,38].Long-term,IFN-basedtreatment
did not halt the progression of chronic HCV infections
in patients not responding to initial treatment [36]. A
variablepercentageofpatientstreatedwithIFNdevelopanti-
IFN antibodies, but surprisingly, there appears to be little
correlation between the presence of such antibodies and the
response to IFN [39]. IFN-α is also useful in the treatment of
cryoglobulinemia and focal glomerulopathy, complications
of chronic HCV infections [40].
Unfortunately, the prolonged peginterferon therapy nec-
essary to control chronic HCV or HBV infections was often
associated with serious side eﬀects such as fatigue, fever,
and myalgias, symptoms of many acute virus infections,
possibly because such eﬀects are due to the induction
of IFNs by the infecting agents. Usually these symptoms
respond to treatment with nonsteroidal anti-inﬂammatory
agents [27]. In some patients, treatment with IFNs has also
resulted in psychiatric problems such as depression, anxiety,
and excessive irritability that may require treatment with
psychoactive pharmaceuticals. More severe toxicities, such as
cytopenias and autoimmune disorders, also have rarely been
reported in patients treated with IFNs [41].
In patients who did not respond to standard pegin-
terferon/ribavirin therapy, substitution of the consensus
interferon, alfacon-1, plus ribavirin proved eﬀective in some
cases [42]. Currently, new forms of therapy to augment
treatment with ribavirin/peginterferon are under develop-
ment, including inhibitors of the HCV protease, helicase,
or polymerase and IFN-α conjugated to albumin [43].
Telaprevir, an inhibitor of the HCV nonstructural protease
NS3/4, has proven to be eﬀective when employed with
peginterferon/ribavirin to treat patients with chronic HCV
infections that are unresponsive to conventional peginter-
feron/ribavirin therapy [44]. Combinations of additional
new agents with the currently employed therapies may
provide eﬀective treatment for a much larger percentage of
HCV patients than are currently responding to anti-HCV
treatment [31].
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